BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 16330675)

  • 1. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
    Randall ME; Filiaci VL; Muss H; Spirtos NM; Mannel RS; Fowler J; Thigpen JT; Benda JA;
    J Clin Oncol; 2006 Jan; 24(1):36-44. PubMed ID: 16330675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation.
    Fowler JM; Brady WE; Grigsby PW; Cohn DE; Mannel RS; Rader JS
    Gynecol Oncol; 2009 Mar; 112(3):553-7. PubMed ID: 19135232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
    Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
    Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
    Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
    Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
    Fleming GF; Brunetto VL; Cella D; Look KY; Reid GC; Munkarah AR; Kline R; Burger RA; Goodman A; Burks RT
    J Clin Oncol; 2004 Jun; 22(11):2159-66. PubMed ID: 15169803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122.
    Randall ME; Spirtos NM; Dvoretsky P
    J Natl Cancer Inst Monogr; 1995; (19):13-5. PubMed ID: 7577198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
    Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
    J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole abdominal irradiation in endometrial cancer - a single institution study.
    Gocheva L; Slavchev B
    J BUON; 2009; 14(4):613-8. PubMed ID: 20148451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
    McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
    Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study.
    Tewari KS; Filiaci VL; Spirtos NM; Mannel RS; Thigpen JT; Cibull ML; Monk BJ; Randall ME
    Gynecol Oncol; 2012 Apr; 125(1):87-93. PubMed ID: 22155678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
    Modesitt SC; Tian C; Kryscio R; Thigpen JT; Randall ME; Gallion HH; Fleming GF;
    Gynecol Oncol; 2007 Apr; 105(1):59-65. PubMed ID: 17150247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
    Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
    Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
    McMeekin DS; Walker JL; Hartenbach EM; Bookman MA; Koh WJ;
    Gynecol Oncol; 2009 Jan; 112(1):134-41. PubMed ID: 18962846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients.
    Bruzzone M; Miglietta L; Franzone P; Gadducci A; Boccardo F
    Gynecol Oncol; 2004 May; 93(2):345-52. PubMed ID: 15099944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
    Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
    J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A feasibility study of doxorubicin/cisplatin (AP) for postoperative chemotherapy in patients with advanced endometrial cancer].
    Nishio S; Katsumata N; Tanabe H; Matsumoto K; Yonemori K; Kouno T; Shimizu C; Ando M; Fujiwara Y
    Gan To Kagaku Ryoho; 2006 Nov; 33(11):1589-93. PubMed ID: 17108724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma.
    Burke TW; Gershenson DM; Morris M; Stringer CA; Levenback C; Tortolero-Luna G; Baker VV
    Gynecol Oncol; 1994 Oct; 55(1):47-50. PubMed ID: 7959265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    Long HJ; Bundy BN; Grendys EC; Benda JA; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV;
    J Clin Oncol; 2005 Jul; 23(21):4626-33. PubMed ID: 15911865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy.
    Kuoppala T; Mäenpää J; Tomas E; Puistola U; Salmi T; Grenman S; Lehtovirta P; Fors M; Luukkaala T; Sipilä P
    Gynecol Oncol; 2008 Aug; 110(2):190-5. PubMed ID: 18534669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
    Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG
    Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.